The read at a glance
Computed from the FY2024 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -37.38 — distress zone — historically elevated failure riskWatch
Leadership changes
From Iterum Therapeutics plc's own filings, the day they're filed.
- Corey Fishman · Chief Executive Officer · departureeff. 2026-03-27
- Judith Matthews · Chief Financial Officer · departureeff. 2026-03-27
- David Kelly · Chairman · departureeff. 2025-03-10
Latest filings
- 8-K · Company announcement2026-03-31
- 8-K · Company announcement2026-03-27
- 8-K · Company announcement2026-03-03
- 8-K · Company announcement2026-03-02
- 8-K · Company announcement2026-02-18
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Iterum Therapeutics plc, every answer cited🔒
- The Intelligence Brief — added when Iterum Therapeutics plc's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.